摘要
目的:分析尤瑞克林联合尿激酶溶栓治疗急性脑梗死临床效果及对患者NIHSS评分、血清炎性因子及预后结局的影响。方法:选取2018年6月-2020年7月因急性脑梗死于雷州市人民医院进行治疗的107例患者作为研究对象,采用随机数字表法分组,对照组(53例)予以尤瑞克林治疗,观察组(54例)采用尤瑞克林联合尿激酶溶栓治疗。对比两组临床疗效、神经功能状况及血清炎性因子指标的差异。结果:观察组临床治疗有效率(94.44%vs73.58%)明显高于对照组(P<0.05);观察组治疗后NIHSS评分[(12.52±1.80)vs(16.35±1.87)]明显低于对照组(P<0.05);观察组治疗后降钙素原(PCT)[(0.17±0.04)vs(0.32±0.06)]、C反应蛋白(CRP)[(5.25±0.72)vs(7.96±0.69)]、白介素6(IL-6)[(9.17±1.56)vs(12.90±1.63)]水平明显低于对照组(P<0.05);观察组治疗后心理功能[(72.45±4.44)vs(63.18±4.36)]、躯体功能[(71.54±6.40)vs(60.18±6.03)]、社会功能[(78.65±5.48)vs(63.51±6.03)]、情感职能[(72.65±7.61)vs(64.35±6.32)]评分明显高于对照组(P<0.05)。结论:尤瑞克林联合尿激酶溶栓治疗急性脑梗死临床效果显著,联合用药明显提高了患者神经功能,改善炎症反应,提高生活质量,可考虑临床推广应用。
Objective: To analyze the clinical effect of eurekline combined with urokinase thrombolytic therapy in patients with acute cerebral infarction and the influence on NIHSS score, serum inflammatory factors and prognosis. Methods: A total of 107 patients with acute cerebral infarction treated in the hospital from June 2018 to July 2020 were selected as study subjects. Randomized number table method was used to divide them into two groups. The control group(53 cases) was treated with Eurekline, while the observation group(54 cases) was treated with Eurekline combined with urokinase thrombolytic therapy. The clinical efficacy,neurological function and serum inflammatory factors were compared between the two groups. Results: The effective rate of clinical treatment in the observation group(94.44% vs 73.58%) was significantly higher than that in the control group(P<0.05). The NIHSS score after treatment in the observation group([12.52±1.80] vs [16.35±1.87]) was significantly lower than that in the control group(P<0.05). After treatment, PCT([0.17±0.04] vs [0.32±0.06]), CRP([5.25±0.72] vs [7.96±0.69]) and IL-6([9.17±1.56] vs(12.90±1.63]) levels in the observation group were significantly lower than those in the control group(P<0.05). The scores of psychological function([72.45±4.44] vs [63.18±4.36]), physical function([71.54±6.40] vs [60.18±6.03]), social function([78.65±5.48]vs [63.51±6.03]) and emotional function([72.65±7.61] vs [64.35±6.32]) in the observation group were significantly higher than those in the control group(P<0.05). Conclusion: Eurekline combined with urokinase thrombolytic therapy for acute cerebral infarction has a significant clinical effect. Combined therapy significantly improves the patients’ neurological function, improves the inflammatory response and the quality of life. Therefore, clinical application should be considered.
作者
曹至更
CAO Zhi-geng(Department of Neu-rology,Leizhou People's Hospital,Leizhou,Guangdong,524200,China)
出处
《黑龙江医学》
2021年第15期1614-1616,共3页
Heilongjiang Medical Journal
基金
湛江市科技计划项目(2020B01289)。
关键词
尤瑞克林
尿激酶溶栓
急性脑梗死
血清炎性因子
神经功能
Eureklin
Urokinase thrombolysis
Acute cerebral infarction
Serum inflammatory factors
Nerve function
